Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Peptide Drug Conjugate (PDC) R&D Service Platform

Peptide Drug Conjugate (PDC) R&D Service Platform

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

Peptide Drug Conjugate (PDC) R&D Service Platform

Medicilon relies on its strong drug innovation technology strength, integrates the company's internal superior resources, and joins forces among departments to build a platform for Medicilon's peptide drug conjugate (PDC) research and development into a technologically with advanced platform, complete supporting facilities and functions and standardized operation. It can form a comprehensive innovative drug research and development platform with integrated innovation capabilities, develop and provide key technologies, and can provide services such as the research and innovative peptide drugs, new peptide dosage forms, and peptide generic drugs.
Medicilon Peptide Drug Conjugate (PDC) R&D Service Platform
Advantages of Medicilon PDC R&D Service Platform
PDC R&D Key Technologies

Learn more about "Peptide Drug Conjugate (PDC) R&D Service"

Relevant laboratories
prev page next page
  • pipette
  • NMR
  • High activity laboratory
  • Overnight synthesis laboratory
  • ICP-MS
  • HPLC
Return